Company Overview of Cambridge Major Laboratories, Inc.
Cambridge Major Laboratories, Inc. provides active pharmaceutical ingredient (API) development and manufacturing services. It provides services from concept to commercialization to supply APIs; process chemistry solutions; and process research services aimed at scouting alternate routes to existing molecules. The company also provides solid state chemistry services, which include crystallization study, material characterization, solubility determination, salt selection, polymorph study, crystallization process development, and crystal habit optimization. Cambridge Major Laboratories, Inc. was formerly known as Cambridge Chemical Inc. and changed its name to Cambridge Major Laboratories, Inc....
W130 N10497 Washington Drive
Germantown, WI 53022
Key Executives for Cambridge Major Laboratories, Inc.
Founder, Non-Executive Chairman and Scientific Advisor
Compensation as of Fiscal Year 2015.
Cambridge Major Laboratories, Inc. Key Developments
AAIPharma Services Corp./Cambridge Major Laboratories Plans to Invest in North Carolina Laboratories and Headquarters
Nov 27 15
AAIPharma Services Corp./Cambridge Major Laboratories is planning to invest around USD 15.8 million to expand its laboratories and global headquarters in Wilmington, North Carolina. The Wilmington site expansion will include up to 40,000 square feet of expanded development services capacity and a new administration building that will become the global headquarters for the company. AAIPharma/CML recently received approval for up to USD 500,000 in incentives from local city and county governments over the next five years.
AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Expands Disinfectant Effectiveness/Qualification Services in St. Louis, MO
Sep 29 15
AAIPharma Services Corp. /Cambridge Major Laboratories, Inc. (AAI/CML) has recently expanded its service capabilities to offer two sites as options for placement of Disinfectant Effectiveness/Disinfectant Qualification (DE/DQ) studies. In order to meet a high customer demand, provide regional support and complement the existing services from the Edison, NJ, facility, AAI/CML now offers DE/DQ at its St. Louis, MO facility. These studies satisfy the requirements of USP Disinfectants and Antiseptics and support clients with their needs to comply with cGMP 21 CFR 211.67, Equipment Cleaning and Maintenance. The expansion allows AAI/CML to further support sterile and non-sterile product manufacturers in the development and qualification of disinfectant programs to prevent microbial contamination through pharmaceutical ingredients, process water, packaging components, manufacturing environment, process and manufacturing equipment.
AAIPharma Services and Cambridge Major Laboratories Announce Manufacturing Agreement for Atossa's Afimoxifene Gel
Aug 5 15
Atossa Genetics Inc. announced that it has signed manufacturing and quality agreements with AAIPharma Services Corp. /Cambridge Major Laboratories, Inc. (AAI/CML) for the manufacturing of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient (API) in Atossa's lead drug candidate, Afimoxifene Gel. In May 2015, Atossa acquired from Besins Healthcare the exclusive rights to Afimoxifene Gel for the potential treatment of hyperplasia of the breast.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|